Philip Morris International Progresses Towards Smoke-Free Future

Sep.16.2022
Philip Morris International Progresses Towards Smoke-Free Future
PMI aims to end cigarette sales and promote smoke-free alternatives, with decreasing sales and increasing investment in innovation products.

PMI is often asked if it truly intends to end cigarette sales.


The answer is: yes.


Philip Morris International acknowledges that the decline in cigarette sales - or broadly speaking, the decline in the combustible product portfolio of PMI - is a necessary component in achieving its ambitions for a smoke-free future.


Fimo International is rapidly making progress towards this goal.


According to data publicly released by Fumo International, their cigarette sales have been on a downward trend for the past decade.


The annual sales volume of cigarettes has declined from 91.5 billion units in 2011 to 62.5 billion units in 2021, decreasing every year over the past nine years.


Furthermore, PMI has set a target for the total shipment of combustible products to be below 550 billion units by 2025, as stated in their 2021 comprehensive report.


The cigarette shipments of PMI (Phillip Morris International) have decreased from 915 billion in 2011 to 625 billion in 2021.


Phimo International aims to ultimately replace cigarettes with smoke-free alternatives.


Since 2008, Philip Morris International has invested over 9 billion dollars in the research and development, product development, production capabilities, scientific validation, and understanding of adult smokers for these innovative products.


This is a successful investment as an increasing number of adult smokers are switching to FiMO International's heated tobacco products, leading to a reduction in cigarette transportation volume.


As of June 30th, 2022, approximately 13.2 million adult smokers have switched to smoke-free alternatives and quit smoking.


The shipment volume of PhiMo International's heated tobacco devices has increased from 7 billion in 2016 to 95 billion in 2021.


These figures are transparently released annually by Fimo International for anyone to access.


Although the optimal choice for any smoker is to completely quit smoking and nicotine, scientifically proven smokeless products are a better option for adult smokers who would otherwise continue smoking.


According to Moira Gilchrist, VP of Strategic and Scientific Communication at Philip Morris International, the company's decision to unilaterally stop selling cigarettes tomorrow will not change anything. "Because it doesn't eliminate the demand for cigarettes. The demand will remain, and others will simply fill it, whether it be competitors or participants in the black market.


Our transition is more significant because we are striving to reduce the long-term demand for cigarettes, ensuring that the decline in the number of smokers continues - and may even accelerate further.


These numbers cannot be ignored," said Stefano Volpetti, President of the PMI Smoke-Free Products category and Chief Consumer Officer. "They clearly depict the transformation that Philip Morris International is driving - first, providing a range of better alternatives for adult smokers and secondly, accelerating smoking cessation.


Our scientific evidence confirms that PMI's smoke-free products, while not without risk, are a better choice than cigarettes for adults who would otherwise continue to smoke.


With support from the industry, stakeholders, and civil society, we believe that cigarette sales can come to an end in many countries within 10 to 15 years. This would be an enduring achievement for the global population of 1 billion smokers, global public health, and our company.


As of June 30, 2022, Philip Morris International (PMI) estimates that approximately 13.2 million adult individuals worldwide (excluding Russia and Ukraine) have switched to their heated tobacco products and quit smoking. These user statistics are reflective of PMI's estimates, which are based on consumer statements and sample-based statistical evaluations, with an average margin of error of +/-5% within the 95% confidence interval in key quantity markets. The accuracy and reliability of user statistics may vary depending on the maturity of individual markets and the availability of information.


Statement:


The content of this article is compiled from third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the authenticity and accuracy of the content. The translation of this article is for industry exchange and research purposes only.


Due to the limitations of the translator's skills, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.


2FIRSTS’ viewpoints and statements on any domestic, Hong Kong, Macau, Taiwan, or international issues are entirely aligned with those of the Chinese government.


The copyright of compiled information belongs to the original media outlet and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
JTI’s Nordic Spirit Signs Co-op Live Partnership Ahead of New UK Nicotine Sponsorship Restrictions
JTI’s Nordic Spirit Signs Co-op Live Partnership Ahead of New UK Nicotine Sponsorship Restrictions
JTI nicotine pouch brand Nordic Spirit has entered a long-term partnership with Manchester’s Co-op Live, becoming the venue’s Official Nicotine Pouch Partner. The 23,500-capacity venue is the UK’s largest indoor live entertainment arena. Nordic Spirit will run in-venue activations for existing adult nicotine consumers and sell products at selected arena bars. The agreement was entered into before the relevant UK sponsorship restrictions were introduced, while the government intends to implement a comprehensive ban on advertising and sponsorship of vaping and nicotine products from June 1, 2027.
Sep.07
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Managing Director Naeem Shahab Khan met Perlis Mufti Mohd Asri Zainul Abidin on September 17 and presented the company's shift from conventional cigarettes toward alternative products. The mufti said a product could be considered halal if it is clean, its side effects are not harmful or can be controlled, and it does not involve excessive waste. His remarks did not mention IQOS or any other specific PMI product and did not amount to a new product-specific religious ruling. It was at least the second publicly reported engagement between Philip Morris Malaysia and a Malaysian religious institution over cigarette alternatives within six months.
Regulations
Sep.18 by 2Firsts Perspectives
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20